Using AI to predict molecular pathology in glioma patients
MR Based Prediction of Molecular Biomarkers or Subgroups in Primary Glioma Using Deep Learning or Machine Learning
This study is trying to see if using AI can help predict the specific molecular features of gliomas in patients by looking at their MRI scans and other data to improve treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 1 Year to 95 Years |
| Sex | All |
| Sponsor | The First Affiliated Hospital of Zhengzhou University Academic / other |
| Locations | 1 site (Zhengzhou, Henan) |
| Trial ID | NCT04217018 on ClinicalTrials.gov |
What this trial studies
This observational registry collects clinical, molecular, and radiologic data from patients with primary gliomas to develop artificial intelligence algorithms that predict molecular pathology. The study focuses on non-invasive imaging techniques, including various MRI sequences, to enhance the accuracy of predictions related to molecular biomarkers such as 1p/19q co-deletion and MGMT methylation. By analyzing a large dataset of over 1000 patients, the aim is to refine predictive models that can assist in personalized treatment approaches for glioma patients.
Who should consider this trial
Good fit: Ideal candidates include patients with a confirmed diagnosis of primary glioma who are scheduled for tumor resection and have a life expectancy of more than three months.
Not a fit: Patients without gliomas or those who cannot provide sufficient tumor tissue for molecular analysis will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate and personalized treatment strategies for glioma patients based on their molecular pathology.
How similar studies have performed: Other studies utilizing AI for predicting molecular pathology in gliomas have shown promise, indicating that this approach is both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients must have radiologically and histologically confirmed diagnosis of primary glioma * Life expectancy of greater than 3 months * Must receive tumor resection * Signed informed consent Exclusion Criteria: * No gliomas * No sufficient amount of tumor tissues for detection of molecular pathology * Patients who have any type of bioimplant activated by mechanical, electronic, or magnetic devices * Patients who are pregnant or breast feeding * Patients who are suffered from severe systematic malfunctions
Where this trial is running
Zhengzhou, Henan
- Department of Neurosurgery, First Affiliated Hospital of Zhengzhou University — Zhengzhou, Henan, China (Recruiting)
Study contacts
- Study coordinator: Zhenyu Zhang, Dr.
- Email: fcczhangzy1@zzu.edu.cn
- Phone: +86 17839973727
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.